272 related articles for article (PubMed ID: 31954274)
1. Combined evaluation of the expression status of CD155 and TIGIT plays an important role in the prognosis of LUAD (lung adenocarcinoma).
Sun Y; Luo J; Chen Y; Cui J; Lei Y; Cui Y; Jiang N; Jiang W; Chen L; Chen Y; Kuang Y; Tang K; Ke Z
Int Immunopharmacol; 2020 Mar; 80():106198. PubMed ID: 31954274
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of CD155/TIGIT expression in patients with colorectal cancer.
Murakami D; Matsuda K; Iwamoto H; Mitani Y; Mizumoto Y; Nakamura Y; Matsuzaki I; Iwamoto R; Takahashi Y; Kojima F; Murata SI; Yamaue H
PLoS One; 2022; 17(3):e0265908. PubMed ID: 35324958
[TBL] [Abstract][Full Text] [Related]
3. Ectopic Expression of TIGIT in Lung Adenocarcinoma and Its Clinical Significance.
He S; Qian N; Ren S; Ma C; Shen D; Tian Y
Crit Rev Eukaryot Gene Expr; 2024; 34(3):27-36. PubMed ID: 38305286
[TBL] [Abstract][Full Text] [Related]
4. CD155 Overexpression Correlates With Poor Prognosis in Primary Small Cell Carcinoma of the Esophagus.
Zhao K; Ma L; Feng L; Huang Z; Meng X; Yu J
Front Mol Biosci; 2020; 7():608404. PubMed ID: 33490104
[TBL] [Abstract][Full Text] [Related]
5. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma.
Chen D; Luo L; Liang C
PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.
Zhang JT; Lin YC; Xiao BF; Yu BT
Med Sci Monit; 2019 Jun; 25():4264-4272. PubMed ID: 31175804
[TBL] [Abstract][Full Text] [Related]
7. Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.
Luo B; Sun Y; Zhan Q; Luo Y; Chen Y; Fu T; Yang T; Ren L; Xie Z; Situ X; Liu B; Tang K; Ke Z
Clin Transl Med; 2024 Jan; 14(1):e1553. PubMed ID: 38279870
[TBL] [Abstract][Full Text] [Related]
8. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
Zhang J; Sun G; Mei X
Cancer Biomark; 2019; 26(3):367-373. PubMed ID: 31594212
[TBL] [Abstract][Full Text] [Related]
9. Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
Inozume T; Yaguchi T; Furuta J; Harada K; Kawakami Y; Shimada S
J Invest Dermatol; 2016 Jan; 136(1):255-63. PubMed ID: 26763445
[TBL] [Abstract][Full Text] [Related]
10. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
11. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.
Duan X; Liu J; Cui J; Ma B; Zhou Q; Yang X; Lu Z; Du Y; Su C
Mol Med Rep; 2019 Oct; 20(4):3773-3781. PubMed ID: 31485637
[TBL] [Abstract][Full Text] [Related]
12. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
13. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
14. CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.
Jiang C; Qu X; Ma L; Yi L; Cheng X; Gao X; Wang J; Che N; Zhang H; Zhang S
Clin Exp Immunol; 2022 Jun; 208(2):220-232. PubMed ID: 35262683
[TBL] [Abstract][Full Text] [Related]
15. CD155T/TIGIT Signaling Regulates CD8
He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
[TBL] [Abstract][Full Text] [Related]
16. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
17. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Xu Y; Cui G; Jiang Z; Li N; Zhang X
Oncol Lett; 2019 Mar; 17(3):2960-2968. PubMed ID: 30854074
[TBL] [Abstract][Full Text] [Related]
19. CD155, an onco-immunologic molecule in human tumors.
Gao J; Zheng Q; Xin N; Wang W; Zhao C
Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595
[TBL] [Abstract][Full Text] [Related]
20. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Zhou F; Wang X; Liu F; Meng Q; Yu Y
Int J Clin Oncol; 2020 Sep; 25(9):1612-1623. PubMed ID: 32430734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]